Pregnant women with severe mitral stenosis tend to experience clinical decompensation with approximately 50% mortality and they may experience adverse effects of the medication they are taking, notably congenital malformations from warfarin exposure. Corrective heart surgery may increase the risk of pregnancy loss. We present 2 cases of RHD in pregnancy. The first case was a 27-year-old patient in her first pregnancy with severe mitral stenosis. Caesarean section was done for foetal distress and she delivered a small for gestational age baby. She was closely monitored postpartum and was stable on discharge. She presented with supraventricular tachycardia and died in the coronary care unit 4 weeks postpartum. The second case was a 28-year-old who was on warfarin for a mechanical mitral valve. A foetal anomaly scan done at 20 weeks showed severe congenital malformations which were not compatible with extra-uterine life. The pregnancy was terminated and she recovered well.
Introduction
Cardiovascular disease complicates 1% to 3% of all pregnancies and accounts for 10% to 15% of maternal mortality [1] . In low income countries Rheumatic Heart Disease (RHD) accounts for approximately 90% of all cardiovascular disease among pregnant women [2] . RHD is a disease of the young and its impact is seen in women of reproductive age. For some of these women an initial diagnosis is made antenatal or postpartum, as they fail to tolerate the impact of the physiological changes of pregnancy on their damaged heart valves resulting in clinical decompensation [1] .
Symptomatic mitral stenosis (MS) has been associated with higher risk for antenatal hospital admission and approximately 50% mortality, which occurs most commonly in the postpartum period [3] . Though pregnancy for most women is indolent, it presents unique challenges for women with RHD. Besides the impact of the pregnancy and delivery on the heart, considerations also have to be made on the impact of RHD therapy on the foetus. Some medical therapies may be teratogenic, while surgical management in pregnancy may increase the risk of pregnancy loss. We present 2 cases of RHD in pregnancies with adverse maternal and foetal outcomes respectively. She expelled the conceptus complete within 24hrs of induction.
Patient and observation
There was no excessive bleeding and she was discharged in a stable condition. Copper T intrauterine contraceptive device (Cu-IUCD) was offered.
Discussion
We have presented 2 cases with valvular damage secondary to RHD who complicated with maternal death and congenital malformations [7] . On the other hand, unfractionated heparin and LMWH are associated with an increased incidence of thromboembolism in patients with MHVs [6] . Women on warfarin are considered to be at risk of having a foetus with neural tube defects (NTD) and should be on 5mg of Folate supplementation. Supplementation should be started preconception [8] . The second case was unfortunately started on folate at 10 weeks gestation which was her first visit.
The first case was put on propranolol to control persistent tachycardia. Arrhythmias such as atrial fibrillation and ventricular tachycardia are common complications in patients with RHD. The atrial and ventricular rate and rhythm can be controlled by using selective oral beta-blockers, calcium channel blockers, amiodarone or digoxin [9] . Although a systematic review could not make conclusions on the effect of beta-blockers like propranolol on perinatal mortality and preterm birth, there was sufficient evidence that they do increase neonatal bradycardia and small for gestational age infants, apnoea, hypoglycaemia and hyperbilirubinemia [10] .
The baby had low birth weight which might be attributed to intrauterine propranolol exposure. Non-selective beta-blockers like labetalol have fewer documented adverse foetal outcomes, but do not have proven efficacy in the treatment of arrhythmias.
Amiodarone use in pregnancy has been associated with transient hypothyroidism, goitre and mild neurodevelopmental abnormalities in the foetus or new born. It is only indicated where maternal tachyarrhythmia is refractory to other safer drugs [11] . Digoxin easily crosses the placental barrier and is associated with increased risk for miscarriage and foetal death when the mother is taking very high doses [12] . The 1 st case decompensated a month after delivery and died under physician care. The risk of maternal mortality is highest in the third trimester and puerperium [3] . 
